This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing label radiodiagnostic agents. Specifically, the invention relates to linear peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to linear peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention so specifically relates to liner peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provide.
The invention features novel somatostatin analogs that may be readily labeled with toxic or non-toxic detectable labels. These unlabeled and labeled analogs are useful for specifically targeting somatostatin receptor bearing cells, in particular neoplastic cells. Labeled analogs are useful, for example, for tumor localization and detection. Where labeled with a toxic label (e.g., radioactivity), the analogs are useful for the targeted delivery of toxicity to somatostatin receptor-bearing cells, in particular neoplastic cells. Also disclosed are methods for treating and detecting neoplasms, and methods for imaging somatostatin receptor-bearing cells.
Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic agent, detectable label or chelating group, and Q is a biologically active peptide. In peptide agents of the invention Y is optionally a hydrophilic polymer or peptide, and Z is a linking peptide bonded to Q at the amino terminus of Q, having two, three, four, or five, amino acid residues selected to link X to Q, while retaining the biological activity of Q. Methods of using these peptide agents in the diagnosis and treatment of diseases are also disclosed.
The invention provides methods and compositions for diagnosing and treating subjects using EBPs. Specifically disclosed are peptides and peptidomimetics that bind selectively to the extracellular domain of ErbB2. These compositions are useful in the prevention and treatment of disorders characterized by ErbB2 overexpression (e.g., breast cancer).
This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.
A technique for localizing an internal bleeding site in the human body is provided. The technique entails the injection of radioactively labelled protein or factor used in the clotting process in solution into a human body When the protein or factor has built up in sufficient quantities at a bleeding site to form a clot, the radioactive emission is used to detect the location of the clot. One or more passes of the detector can be used to accurately pinpoint the location of the clot, and thereby, locate the bleeding site.
